Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Vaxcyte stock on May 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

Vaxcyte Price Performance

Vaxcyte stock opened at $45.42 on Thursday. The firm has a 50 day simple moving average of $54.72 and a 200-day simple moving average of $52.70. Vaxcyte, Inc. has a 1-year low of $29.08 and a 1-year high of $65.00. The stock has a market cap of $6.56 billion, a price-to-earnings ratio of -6.60 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter last year, the firm earned ($1.04) EPS. Equities analysts expect that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In related news, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the sale, the chief operating officer owned 158,494 shares in the company, valued at approximately $7,848,622.88. This trade represents a 1.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the completion of the sale, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. This trade represents a 9.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,392 shares of company stock valued at $524,426 in the last quarter. 3.30% of the stock is owned by insiders.

Institutional Trading of Vaxcyte

Several institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its holdings in Vaxcyte by 23.8% in the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after purchasing an additional 3,188,687 shares during the last quarter. Vanguard Group Inc. increased its holdings in Vaxcyte by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 12,320,453 shares of the company’s stock valued at $443,783,000 after purchasing an additional 323,368 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in Vaxcyte by 35.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after purchasing an additional 2,981,038 shares during the last quarter. Wellington Management Group LLP increased its holdings in Vaxcyte by 18.5% in the 4th quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock valued at $275,286,000 after purchasing an additional 933,539 shares during the last quarter. Finally, State Street Corp increased its holdings in Vaxcyte by 4.1% in the 4th quarter. State Street Corp now owns 4,980,005 shares of the company’s stock valued at $229,777,000 after purchasing an additional 194,116 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

PCVX has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Finally, BTIG Research increased their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Vaxcyte has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.